NDA SUBMISSIONS COULD BE PARED BACK TO SUMMARY DATA, PhRMA SUGGESTS IN PREVIEW OF REFORM PROPOSAL; BIO SPOKESMAN SAYS FDA CENTERS COULD BE CONSOLIDATED
Executive Summary
Summary analyses of preclinical and clinical trials should be sufficient to satisfy FDA's needs for premarket data review, according to the FDA reform plan being prepared by the Pharmaceutical Research & Manufacturers of America.